“Pharmacokinetic results presented by our partner Inspiration Biopharmaceuticals emphasize the encouraging medical potential of IB1001, a promising factor IX for the treatment of hemophilia B, a disease for which access to adequate care is a significant unmet medical need globally.”
Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that its partner Inspiration Biopharmaceuticals, Inc. (Inspiration) presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B. According to Inspiration, results of the Phase 1 portion of an ongoing IB1001 clinical study demonstrated non-inferiority of IB1001 in achieving overall levels of replacement factor compared to BeneFIX®, the only approved recombinant FIX product for the treatment of hemophilia B. Currently, IB1001 is in Phase 3 and safety and efficacy results are expected later this year.
The clinical results were presented at the 4th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) in Geneva, Switzerland, in a poster presentation titled, "Pharmacokinetics of IB1001, a New Recombinant Factor IX".
Marc de Garidel, Chairman and Chief Executive Officer of Ipsen said: "Pharmacokinetic results presented by our partner Inspiration Biopharmaceuticals emphasize the encouraging medical potential of IB1001, a promising factor IX for the treatment of hemophilia B, a disease for which access to adequate care is a significant unmet medical need globally."